Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Trial Profile

Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Pegaspargase (Primary) ; Clofarabine; Crisantaspase; Cyclophosphamide; Cytarabine; Dasatinib; Daunorubicin; Dexamethasone; Doxorubicin; Etoposide; Mercaptopurine; Methotrexate; Prednisone; Tioguanine; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Acronyms TOT-XVI
  • Most Recent Events

    • 07 Apr 2017 Planned End Date changed from 30 Nov 2019 to 30 Nov 2020.
    • 07 Apr 2017 Planned primary completion date changed from 30 Nov 2019 to 30 Nov 2020.
    • 07 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top